• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    87.93 +0.62 (+0.71%)
    Streaming Delayed Price Updated: 9:54 AM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 136,025
    Open 87.04
    Bid (Size) 87.92 (1)
    Ask (Size) 87.98 (2)
    Prev. Close 87.31
    Today's Range 86.36 - 88.18
    52wk Range 53.56 - 92.86
    Shares Outstanding 222,430,635
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Incyte (INCY) Stock Is Up, What You Need To Know
    Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic... 
    Via StockStory
    Topics Artificial Intelligence
    Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +26.5%
    +26.5%
    1 Month
    +4.8%
    +4.8%
    3 Month
    +27.5%
    +27.5%
    6 Month
    +51.1%
    +51.1%
    1 Year
    +32.9%
    +32.9%

    More News

    Read More
    Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
    From Incyte
    Via Business Wire
    JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
    Via MarketMinute
    Topics Economy Intellectual Property
    What 14 Analyst Ratings Have To Say About Incyte
    Via Benzinga
    Which S&P500 stocks are gapping on Wednesday?
    Via Chartmill
    Incyte to Report Third Quarter Financial Results
    From Incyte
    Via Business Wire
    2 Reasons to Like INCY and 1 to Stay Skeptical
    Via StockStory
    Topics Stocks
    Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
    Via MarketMinute
    Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
    Via MarketMinute
    Topics Intellectual Property
    Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market
    Via Benzinga
    Topics Stocks
    Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
    From Incyte
    Via Business Wire
    Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
    Via Benzinga
    FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children
    Via Benzinga
    Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate
    Via Chartmill
    Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
    From Incyte
    Via Business Wire
    Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
    From Incyte
    Via Business Wire
    2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
    Via StockStory
    Topics Stocks
    Uncover the latest developments among S&P500 stocks in today's session.
    Via Chartmill
    3 Unpopular Stocks That Deserve a Second Chance
    Via StockStory
    Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
    From Incyte
    Via Business Wire
    Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
    From Incyte
    Via Business Wire
    Incyte (INCY) Stock Is Up, What You Need To Know
    Via StockStory
    Topics Economy
    Tuesday's session: top gainers and losers in the S&P500 index
    Via Chartmill

    Frequently Asked Questions

    Is Incyte Corporation - Common Stock publicly traded?
    Yes, Incyte Corporation - Common Stock is publicly traded.
    What exchange does Incyte Corporation - Common Stock trade on?
    Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Incyte Corporation - Common Stock?
    The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
    What is the current price of Incyte Corporation - Common Stock?
    The current price of Incyte Corporation - Common Stock is 87.93
    When was Incyte Corporation - Common Stock last traded?
    The last trade of Incyte Corporation - Common Stock was at 10/17/25 09:54 AM ET
    What is the market capitalization of Incyte Corporation - Common Stock?
    The market capitalization of Incyte Corporation - Common Stock is 19.56B
    How many shares of Incyte Corporation - Common Stock are outstanding?
    Incyte Corporation - Common Stock has 20B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.